RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Tuberous Sclerosis Complex-associated Refractory Seizures
Conditions
Tuberous Sclerosis Complex-associated Refractory Seizures
Trial Timeline
Apr 29, 2013 → Oct 25, 2017
NCT ID
NCT01713946About RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)
RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase) is a phase 3 stage product being developed by Novartis for Tuberous Sclerosis Complex-associated Refractory Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT01713946. Target conditions include Tuberous Sclerosis Complex-associated Refractory Seizures.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01713946 | Phase 3 | Completed |
Competing Products
13 competing products in Tuberous Sclerosis Complex-associated Refractory Seizures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Everolimus (RAD001) + Everolimus Placebo | Novartis | Phase 3 | 77 |
| Everolimus + Placebo | Novartis | Phase 3 | 77 |
| RAD001 | Novartis | Phase 1/2 | 41 |
| Placebo + Everolimus (RAD001) | Novartis | Phase 2 | 52 |
| RAD001 + Placebo | Novartis | Phase 2 | 52 |
| Everolimus | Novartis | Phase 1/2 | 41 |
| everolimus (RAD001) | Novartis | Phase 1/2 | 41 |
| everolimus | Novartis | Phase 3 | 77 |
| sirolimus | Pfizer | Phase 2 | 51 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| GWP42003-P + Placebo | Jazz Pharmaceuticals | Phase 3 | 74 |
| Cannabidiol Oral Solution [Epidiolex] | Jazz Pharmaceuticals | Approved | 82 |